Recognizing and managing on toxicities in cancer immunotherapy
Over the past 4 years, cancer immunotherapy has significantly prolonged survival time of patients with prostate cancer, melanoma, lung cancer, and liver cancer, but its side effects are also impressive. Different types of the immune therapeutic agents have different on-target or off-target toxicity...
Saved in:
| Main Authors: | Liu Yang, Huifang Yu, Shuang Dong, Yi Zhong, Sheng Hu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-03-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317694542 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiac toxicity of checkpoint inhibitors (CPI) used in cancer immunotherapy
by: Alexandru Grigorescu, et al.
Published: (2023-01-01) -
Incidence of hematological toxicity with use of immunotherapy and chemotherapy in advanced non-small cell lung cancer
by: Wenhai Fu, et al.
Published: (2025-01-01) -
Targeting IL‐17A to manage immunotherapy‐induced toxicity in melanoma
by: Kai Huang
Published: (2025-01-01) -
From Building Corpora for Recognizing Faceted Entailment to Recognizing Relational Entailment
by: Martin Víta
Published: (2018-09-01) -
Editorial: Investigating tumor immunotherapy responses in lung cancer using deep learning
by: Shuang Qin, et al.
Published: (2024-12-01)